Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice

Vaccine

Volumn 32, Issue 30, 2014, Pages 3796-3804

  Wen, Yingxia ^a   Monroe, James ^a   Linton, Christine ^a   Archer, Jacob ^a   Beard, Clayton W ^a   Barnett, Susan W ^a   Palladino, Giuseppe ^a   Mason, Peter W ^a,c   Carfi, Andrea ^a   Lilja, Anders E ^a,b  

^a Novartis Vaccines Cambridge   (United States)

^b HOOKIPA BIOTECH AG   (Austria)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cytomegalovirus; Neutralizing antibodies; Pentameric complex; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; GLYCOPROTEIN H, HUMAN CYTOMEGALOVIRUS; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; MF59 OIL EMULSION; MONOCLONAL ANTIBODY; MULTIPROTEIN COMPLEX; POLYSORBATE; SQUALENE; UL128 PROTEIN, HUMAN CYTOMEGALOVIRUS; UL130 PROTEIN, HUMAN CYTOMEGALOVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ALPHA VIRUS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VIRUS ENTRY; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BLOOD; CYTOMEGALOVIRUS; FEMALE; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; FEMALE; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; MULTIPROTEIN COMPLEXES; POLYSORBATES; REPLICON; SQUALENE; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 84922248300     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.004     Document Type: Article

References (39)

1. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields virology 2007, 2699-2772. Lippincott Williams & Wilkins. D.M. Knipe, P.M. Howley (Eds.).
2. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008, 325:417-470.
3. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008, 8:541-548.
4. Lilja A.E., Mason P.W. The next generation recombinant human cytomegalovirus vaccine candidates-Beyond gB. Vaccine 2012, 30:6980-6990.
5. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., Bernstein D.I. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004, 189:1374-1381.
6. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007, 195:789-798.
7. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990, 64:1079-1085.
8. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010, 84:1005-1013.
9. Mach M., Kropff B., Dal Monte P., Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 2000, 74:11881-11892.
10. Urban M., Klein M., Britt W.J., Hassfurther E., Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996, 77(Pt 7):1537-1547.
11. Rasmussen L., Matkin C., Spaete R., Pachl C., Merigan T.C. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991, 164:835-842.
12. Fouts A.E., Chan P., Stephan J.P., Vandlen R., Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 2012, 86:7444-7447.
13. Potzsch S., Spindler N., Wiegers A.K., Fisch T., Rucker P., Sticht H., et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011, 7:e1002172.
14. Wang D., Li F., Freed D.C., Finnefrock A.C., Tang A., Grimes S.N., et al. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 2011, 29:9075-9080.
15. Urban M., Winkler T., Landini M.P., Britt W., Mach M. Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. J Infect Dis 1994, 169:83-90.
16. Kaye J.F., Gompels U.A., Minson A.C. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product. J Gen Virol 1992, 73(Pt 10):2693-2698.
17. Heldwein E.E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 2008, 65:1653-1668.
18. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008, 82:60-70.
19. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005, 102:18153-18158.
20. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 2006, 87:2451-2460.
21. Akter P., Cunningham C., McSharry B.P., Dolan A., Addison C., Dargan D.J., et al. Two novel spliced genes in human cytomegalovirus. J Gen Virol 2003, 84:1117-1122.
22. Gerna G., Percivalle E., Lilleri D., Lozza L., Fornara C., Hahn G., et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005, 86:275-284.
23. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78:10023-10033.
24. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
25. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999, 180:970-975.
26. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
27. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., Langston A.A., Chu A.H., Wloch M.K., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
28. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197:1634-1642.
29. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
30. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
31. Loomis R.J., Lilja A.E., Monroe J., Balabanis K.A., Brito L.A., Palladino G., et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013, 31:919-926.
32. Sampaio K.L., Cavignac Y., Stierhof Y.D., Sinzger C. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J Virol 2005, 79:2754-2767.
33. Grazia Revello M., Baldanti F., Percivalle E., Sarasini A., De-Giuli L., Genini E., et al. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 2001, 82:1429-1438.
34. Nokta M., Tolpin M.D., Nadler P.I., Pollard R.B. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res 1994, 24:17-26.
35. Kinney R.M., Chang G.J., Tsuchiya K.R., Sneider J.M., Roehrig J.T., Woodward T.M., et al. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. J Virol 1993, 67:1269-1277.
36. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003, 77:10394-10403.
37. Reap E.A., Morris J., Dryga S.A., Maughan M., Talarico T., Esch R.E., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007, 25:7441-7449.
38. Wussow F., Yue Y., Martinez J., Deere J.D., Longmate J., Herrmann A., et al. A vaccine based on the Rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in Rhesus Macaques. J Virol 2013, 87:1322-1332.
39. Fu T.M., Wang D., Freed D.C., Tang A., Li F., He X., et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 2012, 30:7469-7474.